menu
    • menu

    Company profile for Partner Therapeutics

    NEW Drugs in Dev: 2
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    PTx is an U.S.-based commercial-stage biotech company focused on the development and commercialization of therapeutics that improve health outcomes in the treatment of cancer. PTx’s development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company believes in delivering great products with the purpose of creating the best possible outcomes for patients and their families.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Partner TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    19 Muzzey Street Lexington, MA02421
    Telephone
    Telephone
    781-218-9394
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.partnertx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/partner-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/PartnerTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zenocutuzumab Extends Benefits in NRG1+ Pancreatic Cancer
    Zenocutuzumab Extends Benefits in NRG1+ Pancreatic Cancer

    09 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/continued-zenocutuzumab-treatment-beyond-progression-shows-benefit-in-patients-with-nrg1-pancreatic-cancer-and-cholangiocarcinoma-new-results-from-the-enrgy-trial-presented-at-asco-gi-302656811.html

    PR NEWSWIRE
    09 Jan 2026
    Share Share
    Zenocutuzumab Shows Durable Efficacy in NRG1+ NSCLC
    Zenocutuzumab Shows Durable Efficacy in NRG1+ NSCLC

    07 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/zenocutuzumab-zbco-bizengri-shows-durable-efficacy-in-patients-with-treatment-naive-nrg1nsclc-updated-enrgy-trial-results-presented-at-iaslc-asco-naclc-302634170.html

    PR NEWSWIRE
    07 Dec 2025
    Share Share
    Zenocutuzumab-Zbco Receives FDA Breakthrough Designation
    Zenocutuzumab-Zbco Receives FDA Breakthrough Designation

    24 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/zenocutuzumab-zbco-granted-fda-breakthrough-therapy-designation-for-nrg1-cholangiocarcinoma-data-highlighting-potential-of-zenocutuzumab-zbco-in-nrg1-cholangiocarcinoma-to-be-presented-at-aacr-nci-eortc-302593179.html

    PR NEWSWIRE
    24 Oct 2025
    Share Share
    Partner Therapeutics’ Imreplys Receives Approval In Europe
    Partner Therapeutics’ Imreplys Receives Approval In Europe

    21 Aug 2025

    // EMA

    https://www.ema.europa.eu/en/documents/overview/imreplys-epar-medicine-overview_en.pdf

    EMA
    21 Aug 2025
    Share Share
    NEJM Publishes eNRGy Results for Zenocutuzumab in NRG1+ Cancer
    NEJM Publishes eNRGy Results for Zenocutuzumab in NRG1+ Cancer

    05 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-publishes-results-of-global-multicenter-enrgy-study-evaluating-zenocutuzumab-zbco-bizengri-in-nrg1-cancer-302369431.html

    PR NEWSWIRE
    05 Feb 2025
    Share Share
    BARDA, Partner Therapeutics Advance LEUKINE® for Sepsis Treatment
    BARDA, Partner Therapeutics Advance LEUKINE® for Sepsis Treatment

    09 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/barda-and-partner-therapeutics-continue-partnership-around-development-of-leukine-sargramostim-rhu-gm-csf-to-potentially-improve-patient-care-for-sepsis-302347356.html

    PR NEWSWIRE
    09 Jan 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Partner Therapeutics and get a quotation

    Partner Therapeutics is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find a price of Hydroxy Echinocandin bulk with DMF offered by Partner Therapeutics

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search